{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:43:40Z","timestamp":1778877820439,"version":"3.51.4"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008535","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000}}],"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Lassa fever is an haemorrhagic fever caused by Lassa virus (LASV). There is no vaccine approved against LASV and the only recommended antiviral treatment relies on ribavirin, despite limited evidence of efficacy. Recently, the nucleotide analogue favipiravir showed a high antiviral efficacy, with 100% survival obtained in an otherwise fully lethal non-human primate (NHP) model of Lassa fever. However the mechanism of action of the drug is not known and the absence of pharmacokinetic data limits the translation of these results to the human setting. Here we aimed to better understand the antiviral effect of favipiravir by developping the first mathematical model recapitulating Lassa viral dynamics and treatment. We analyzed the viral dynamics in 24 NHPs left untreated or treated with ribavirin or favipiravir, and we put the results in perspective with those obtained with the same drugs in the context of Ebola infection. Our model estimates favipiravir EC<jats:sub>50<\/jats:sub> <jats:italic>in vivo<\/jats:italic> to 2.89 <jats:italic>\u03bc<\/jats:italic>g.mL<jats:sup>-1<\/jats:sup>, which is much lower than what was found against Ebola virus. The main mechanism of action of favipiravir was to decrease virus infectivity, with an efficacy of 91% at the highest dose. Based on our knowledge acquired on the drug pharmacokinetics in humans, our model predicts that favipiravir doses larger than 1200 mg twice a day should have the capability to strongly reduce the production infectious virus and provide a milestone towards a future use in humans.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008535","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:50:32Z","timestamp":1610063432000},"page":"e1008535","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":40,"title":["Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-6220","authenticated-orcid":true,"given":"Guillaume","family":"Lingas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8101-4348","authenticated-orcid":true,"given":"Kyle","family":"Rosenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Safronetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":true,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"pcbi.1008535.ref001","unstructured":"CDC. Estimated number of Lassa fever cases in West Africa each year Death rate from Ebola Death rate from Lassa fever. 2015."},{"issue":"1","key":"pcbi.1008535.ref002","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article","volume":"3","author":"HJ Hallam","year":"2018","journal-title":"npj Vaccines"},{"issue":"2","key":"pcbi.1008535.ref003","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality Among Confirmed Lassa Fever Cases During the 2015\u20132016 Outbreak in Nigeria","volume":"108","author":"MI Buba","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"3","key":"pcbi.1008535.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000388","article-title":"Risk maps of lassa fever in West Africa","volume":"3","author":"E Fichet-Calvet","year":"2009","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"pcbi.1008535.ref005","unstructured":"World Health Organization, Lassa Fever;. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lassa-fever."},{"issue":"5","key":"pcbi.1008535.ref006","first-page":"580","volume":"141","author":"PB Jahbrlsg","year":"1980","journal-title":"Lassa Virus Infection of Rhesus Monkeys: Pathogenesis and Treatment with Ribavirin"},{"issue":"5","key":"pcbi.1008535.ref007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jvp.12394","article-title":"Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration","volume":"40","author":"DU Lee","year":"2017","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"issue":"1","key":"pcbi.1008535.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06215-z","article-title":"Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies","volume":"9","author":"V Madelain","year":"2018","journal-title":"Nature Communications"},{"key":"pcbi.1008535.ref009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"SL Bixler","year":"2018","journal-title":"Antiviral Research"},{"issue":"3","key":"pcbi.1008535.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002535","article-title":"Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques","volume":"15","author":"J Guedj","year":"2018","journal-title":"PLoS Medicine"},{"issue":"9","key":"pcbi.1008535.ref011","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of favipiravir to treat lassa virus infection in Macaques","volume":"24","author":"K Rosenke","year":"2018","journal-title":"Emerging Infectious Diseases"},{"issue":"3","key":"pcbi.1008535.ref012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/17460441.2011.554815","article-title":"Nonhuman primates as models for the discovery and development of ebolavirus therapeutics","volume":"6","author":"AC Shurtleff","year":"2011","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"1","key":"pcbi.1008535.ref013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses","volume":"61","author":"V Madelain","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pcbi.1008535.ref014","doi-asserted-by":"crossref","first-page":"e03679","DOI":"10.7554\/eLife.03679","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"A Arias","year":"2014","journal-title":"eLife"},{"issue":"11","key":"pcbi.1008535.ref015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01400-17","article-title":"Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis","volume":"61","author":"E Escribano-Romero","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"May","key":"pcbi.1008535.ref016","doi-asserted-by":"crossref","first-page":"104529","DOI":"10.1016\/j.antiviral.2019.06.001","article-title":"T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques","volume":"170","author":"N Espy","year":"2019","journal-title":"Antiviral Research"},{"issue":"1","key":"pcbi.1008535.ref017","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.12687","article-title":"Mathematical modeling of within-host Zika virus dynamics","volume":"285","author":"K Best","year":"2018","journal-title":"Immunological Reviews"},{"issue":"33","key":"pcbi.1008535.ref018","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"K Best","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"pcbi.1008535.ref019","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy-predicting effects of treatment","volume":"12","author":"AS Perelson","year":"2015","journal-title":"Nature Reviews Gastroenterology and Hepatology"},{"issue":"4","key":"pcbi.1008535.ref020","first-page":"1395","volume":"47","author":"Cc Lin","year":"2003","journal-title":"Pharmacokinetics and Metabolism of [14 C] Ribavirin in Rats and Cynomolgus Monkeys"},{"issue":"4","key":"pcbi.1008535.ref021","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","article-title":"Maximum likelihood estimation in nonlinear mixed effects models","volume":"49","author":"E Kuhn","year":"2005","journal-title":"Computational Statistics and Data Analysis"},{"issue":"3","key":"pcbi.1008535.ref022","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model","volume":"51","author":"A Samson","year":"2006","journal-title":"Computational Statistics & Data Analysis"},{"issue":"1","key":"pcbi.1008535.ref023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2288-6-38","article-title":"Estimation of dynamical model parameters taking into account undetectable marker values","volume":"6","author":"R Thi\u00e9baut","year":"2006","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"pcbi.1008535.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-020-0426-7","article-title":"Model Averaging in Viral Dynamic Models","volume":"22","author":"A Gon\u00e7alves","year":"2020","journal-title":"AAPS Journal"},{"issue":"2","key":"pcbi.1008535.ref025","first-page":"1","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"THT Nguyen","year":"2017","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"12","key":"pcbi.1008535.ref026","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever","volume":"51","author":"D Bausch","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"pcbi.1008535.ref027","article-title":"Acute bacterial or viral infection\u2014What\u2019s the difference? A perspective from PKPD modellers","author":"LE Friberg","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"pcbi.1008535.ref028","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever","volume":"213","author":"L Oestereich","year":"2015","journal-title":"The Journal of Infectious Diseases"},{"issue":"45","key":"pcbi.1008535.ref029","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"DH Goldhill","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"pcbi.1008535.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-10198-0","article-title":"Determining Ribavirin\u2019s mechanism of action against Lassa virus infection","volume":"7","author":"P Carrillo-Bustamante","year":"2017","journal-title":"Scientific Reports"},{"issue":"3","key":"pcbi.1008535.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea","volume":"13","author":"D Sissoko","year":"2016","journal-title":"PLoS Medicine"},{"issue":"119","key":"pcbi.1008535.ref032","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2016.0289","article-title":"Understanding the within-host dynamics of influenza A virus: From theory to clinical implications","volume":"13","author":"C Hadjichrysanthou","year":"2016","journal-title":"Journal of the Royal Society Interface"},{"issue":"6","key":"pcbi.1008535.ref033","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study","volume":"18","author":"P Okokhere","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"key":"pcbi.1008535.ref034","unstructured":"WHO. Clincial Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker. World Health Organization. 2016; p. 1\u2013191."},{"issue":"1","key":"pcbi.1008535.ref035","doi-asserted-by":"crossref","DOI":"10.3390\/v12010106","article-title":"Modeling Challenges of Ebola Virus\u2013Host Dynamics during Infection and Treatment","volume":"12","author":"DS Chertow","year":"2020","journal-title":"Viruses"},{"issue":"5","key":"pcbi.1008535.ref036","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.micinf.2006.02.002","article-title":"Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages","volume":"8","author":"S Baize","year":"2006","journal-title":"Microbes and Infection"},{"issue":"11","key":"pcbi.1008535.ref037","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys","volume":"83","author":"S Baize","year":"2009","journal-title":"Journal of virology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008535","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T19:43:18Z","timestamp":1611171798000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008535"}},"subtitle":[],"editor":[{"given":"Rustom","family":"Antia","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008535","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1008535","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}